

Does subacromial injection influence shoulder strength?

Submission date 13/04/2011	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 11/05/2011	Overall study status Completed	☐ Protocol
Last Edited 11/05/2011	Condition category Musculoskeletal Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mazda Farshad

Contact details
Forchstrasse 340
Zürich
Switzerland
8008

Additional identifiers

Study information

Scientific Title
Does subacromial injection influence shoulder strength? A double blind placebo controlled study

Study objectives
1. Abduction strength is decreased after subacromial injection of a local anaesthetic (LA) with no radiographical guidance
2. Strength of the deltoid muscle and or supraspinatus muscle is affected after blind subacromial injection of standard dose of a standard LA

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study has been approved by the Ethical Committee of Kanton Zürich on 23rd December 2010

Primary study design

Interventional

Study design

Double blind intra-individual placebo controlled single centre study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Subacromial injection for shoulder pain

Interventions

This study uses a double blind intra-individual placebo controlled design, where each shoulder that undergoes the intervention (subacromial injection of the local anesthetic) has an intra-individual control (the contralateral side) where placebo is applied.

For each of the 10 volunteers, the integrity of the supraspinatus tendon is evaluated with ultrasonography on both sides. Only if no pathology is found on ultrasonography, the volunteer is included in the study. The abduction strength of both shoulders of the 10 healthy volunteers will be measured three times with Isobex (in 30° and 90° Abduction), while superficial electromyography (EMG) documents the activity of the deltoid muscle. Subsequently, randomly and blinded, 5ml 1% Lidocaine in one shoulder and 5ml 0.9% saline solution in the contralateral shoulder will be injected without ultrasonographic guidance aimed to the subacromial space. The injection will be performed blindly because the technique is commonly used in daily clinic and the evidence is not conclusive, although however, might by trend favour the use of ultrasonographic-guided injections. The technique of the injection is based on commonly used aseptic technique with a 21-gauge needle with the covered syringe, into the patients subacromial bursa via the anterolateral approach. Subsequently, the bilateral ultrasonography will be repeated to document the location of the injected fluid.

After 20min, again, the abduction strength of both shoulders will be quantified with Isobex (in 30° and 90° Abduction), while superficial EMG documents the activity of the deltoid muscle.

Neither the injecting physician nor the proband, nor who is measuring the abduction strength, will know which substance is injected.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Strength of shoulder abduction - Each volunteer undergoes an ultrasonography of both shoulders to assure full rotator cuff integrity then abduction strengths are measured.

Subsequently, either on the left or the right shoulder a local anaesthetic is injected. The other side serves as control, where sodium chloride (NaCL) is injected. Then we repeat the ultrasonography to document the location of the injected fluid and repeat the abduction strengths.

Key secondary outcome(s)

Radiographical documentation of location of the aimed subacromial injection

Completion date

30/04/2012

Eligibility

Key inclusion criteria

1. Past medical history not significant for major disorders
2. No shoulder pain
3. No previous operation or injections on the shoulder
4. No allergy to LA

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Do not meet inclusion criteria

Date of first enrolment

30/04/2011

Date of final enrolment

30/04/2012

Locations

Countries of recruitment

Switzerland

Study participating centre

Forchstrasse 340

Zürich

Switzerland
8008

Sponsor information

Organisation

Balgrist University Hospital (Switzerland)

ROR

<https://ror.org/02yzaka98>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Balgrist Universtiy Hospital (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration